SARS-CoV-2 predisposes patients to thrombotic disease due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis [1]. The infection was recognized as an independent risk factor for acute myocardial infarction (AMI), which is considered part of the clinical picture of the COVID-19 disease [2]. Cardiovascular disease increases both the susceptibility to SARS-COV-2 and the risk of death in patients with COVID-19 [3]. Among those who died and were COVID PCR-positive, almost one-third (30%) suffered from ischemic heart disease [4].
